These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32063037)

  • 21. Pragmatic clinical trials in the context of regulation of medicines.
    Gedeborg R; Cline C; Zethelius B; Salmonson T
    Ups J Med Sci; 2019 Jan; 124(1):37-41. PubMed ID: 30251577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good.
    Spellberg B; Marr KA; Brass EP
    Clin Pharmacol Ther; 2016 Dec; 100(6):597-599. PubMed ID: 27626768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
    Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
    Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
    Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Food and Drug Administration and the regulation of clinical trials for endosseous implants.
    Scott PD; Runner S
    Ann Periodontol; 1997 Mar; 2(1):284-90. PubMed ID: 9151561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
    Fang Y; Wang H; He W
    Ther Innov Regul Sci; 2020 Jul; 54(4):749-757. PubMed ID: 32557297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new FDA reality.
    Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):1-2. PubMed ID: 24444470
    [No Abstract]   [Full Text] [Related]  

  • 29. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA oversight of cell therapy clinical trials.
    Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
    Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators.
    Zuidgeest MGP; Welsing PMJ; van Thiel GJMW; Ciaglia A; Alfonso-Cristancho R; Eckert L; Eijkemans MJC; Egger M;
    J Clin Epidemiol; 2017 Oct; 90():92-98. PubMed ID: 28694123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable.
    Dreyer NA
    Ther Innov Regul Sci; 2018 May; 52(3):362-368. PubMed ID: 29714575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative.
    Warner JJ; Crook HL; Whelan KM; Bleser WK; Roiland RA; Hamilton Lopez M; Saunders RS; Wang TY; Hernandez AF; McClellan MB; Califf RM; Brown N;
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006606. PubMed ID: 32683985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Food and Drug Administration and pragmatic clinical trials of marketed medical products.
    Anderson ML; Griffin J; Goldkind SF; Zeitler EP; Wing L; Al-Khatib SM; Sherman RE
    Clin Trials; 2015 Oct; 12(5):511-9. PubMed ID: 26374684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerating development of scientific evidence for medical products within the existing US regulatory framework.
    Sherman RE; Davies KM; Robb MA; Hunter NL; Califf RM
    Nat Rev Drug Discov; 2017 May; 16(5):297-298. PubMed ID: 28232726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality control of oncology clinical trials.
    Meyerson LJ; Wiens BL; LaVange LM; Koutsoukos AD
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):953-71, x. PubMed ID: 10949783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency.
    Krleža-Jeriç K; Lemmens T; Reveiz L; Cuervo LG; Bero LA
    Rev Panam Salud Publica; 2011 Jul; 30(1):87-96. PubMed ID: 22159656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Dunlop phenomena: a lesson in risk management from an unlikely source.
    Williams D
    Med Device Technol; 2003 Apr; 14(3):9-10. PubMed ID: 12789692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act.
    Logvinov I
    Contemp Clin Trials; 2014 Mar; 37(2):219-24. PubMed ID: 24440100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.